+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Disease Testing Market by Test Type, Component, Age Group, Technology, Test Purpose, Diseases Type, End Users - Global Forecast to 2030- Product Image
Respiratory Disease Testing Market by Test Type, Component, Age Group, Technology, Test Purpose, Diseases Type, End Users - Global Forecast to 2030- Product Image
Sale

Respiratory Disease Testing Market by Test Type, Component, Age Group, Technology, Test Purpose, Diseases Type, End Users - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012368
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Respiratory Disease Testing Market grew from USD 6.49 billion in 2024 to USD 6.86 billion in 2025. It is expected to continue growing at a CAGR of 5.95%, reaching USD 9.18 billion by 2030.

Unveiling the Dynamics of Respiratory Disease Testing

The landscape of respiratory disease testing is undergoing a profound transformation driven by advances in diagnostic technologies, shifting regulatory frameworks, and evolving patient needs. As chronic and infectious respiratory conditions place increasing strain on healthcare systems worldwide, laboratories, hospitals, and care providers are prioritizing faster, more accurate testing modalities to improve outcomes and reduce costs. This executive summary provides a concise yet thorough overview of the critical forces shaping this dynamic market and the strategic considerations every stakeholder must weigh. It sets the stage for deeper analysis of tariff impacts, market segmentation, and regional dynamics.

Redefining Respiratory Diagnostics Through Pivotal Shifts

Over the past few years, the respiratory diagnostics arena has witnessed several transformative shifts. Innovations in molecular diagnostics have dramatically shortened turnaround times for detecting pathogens such as influenza and tuberculosis, while artificial intelligence-driven imaging analysis is enhancing the precision of chest X-ray and computed tomography interpretations. At the same time, immunoassay reagents and next-generation sequencing are expanding disease detection capabilities across a broader spectrum of conditions, from asthma phenotyping to early lung cancer screening. Parallel to these technological leaps, control measures for infectious diseases have sharpened focus on decentralized and point-of-care testing, enabling home care settings to play a more prominent role in monitoring chronic obstructive pulmonary disease and other long-term conditions. Taken together, these shifts are redefining value propositions, forcing manufacturers and service providers to adopt integrated solutions that span instruments, kits, software, and data analytics.

Assessing the Rippling Effects of 2025 US Tariff Adjustments

The United States tariff revisions set to take effect in 2025 will introduce new cost pressures across the respiratory testing value chain. Increased duties on imported reagents and high-precision imaging components will elevate input costs for diagnostic laboratories and research facilities. Instrument manufacturers may need to absorb a portion of these escalations to maintain competitive pricing, compressing margins unless offset by operational efficiencies or strategic supply-chain diversification. Meanwhile, domestic reagent and kit producers are positioned to capitalize on reshored manufacturing incentives, potentially accelerating investment in local production capacity. However, compliance costs related to dual tariffs on molecular diagnostics components will necessitate a reevaluation of sourcing strategies. Ultimately, these combined factors will shift procurement dynamics, compelling end users-from hospitals and clinics to home care settings-to renegotiate supplier agreements and explore alternative diagnostic platforms.

Deep-Dive into Market Segments Reveals Diverse Demand Drivers

A nuanced understanding of market segments reveals the multifaceted nature of demand in respiratory disease testing. When viewed through the lens of test type, imaging tests-particularly chest X-ray and computed tomography-are experiencing accelerated adoption due to their critical role in diagnosing lung cancer and severe pneumonia, though blood tests remain essential for biomarker monitoring and pulmonary function tests continue to support asthma and COPD management. Component analysis highlights that instruments constitute the backbone of diagnostic workflows, while reagents and kits drive recurring revenue streams; software solutions are emerging as the connective tissue that integrates data across diverse systems. Age-group segmentation further underscores the differentiated needs of adult, geriatric, and pediatric patients, with tailored receptor profiles and testing frequencies shaping product development priorities. Technological distinctions among imaging methodologies, immunoassays, microbiology platforms, and molecular diagnostics point to divergent regulatory pathways and R&D investment cycles. Within test purposes, diagnostics and screening dominate early-stage interventions, whereas monitoring and prognosis applications are carving out growing niches in chronic care. Disease-type segmentation demonstrates that asthma and lung cancer require distinct assay sensitivities, while divisions within COPD-such as chronic bronchitis and emphysema-and the breakdown of infectious respiratory diseases into influenza, pneumonia, and tuberculosis demand specialized reagent banks. Finally, end users ranging from diagnostic laboratories and research laboratories to hospitals, clinics, and home care settings each prioritize varying throughput, automation levels, and connectivity features.

Regional Footprints Highlight Varied Testing Adoption Trends

Regional nuances exert a powerful influence on respiratory testing strategies and adoption rates. In the Americas, mature healthcare infrastructures support rapid rollout of advanced molecular diagnostic platforms and imaging suites, bolstered by robust reimbursement mechanisms and streamlined regulatory approvals. By contrast, Europe, Middle East & Africa exhibits a dual landscape: Western Europe drives innovation through public-private partnerships and ambitious screening programs, while emerging markets in the Middle East and Africa pursue incremental upgrades in basic immunoassays and point-of-care tests due to budget constraints. Across Asia-Pacific, dynamic economic growth fuels substantial investments in both domestic manufacturing and importation of high-end instruments, particularly in countries prioritizing lung cancer screening and tuberculosis eradication. These regional footprints inform how manufacturers and service providers align commercialization strategies with local policy environments, supply-chain infrastructure, and population health priorities.

Leading Players Shaping the Respiratory Testing Arena

Competitive intensity within the respiratory testing market is defined by a handful of global leaders complemented by agile niche specialists. Major diagnostics conglomerates leverage comprehensive product portfolios-spanning molecular assays, immunoassay reagent lines, and high-throughput imaging equipment-to reinforce long-term contracts with hospital networks and national laboratories. Simultaneously, dedicated biotech firms concentrate on next-generation sequencing panels for infectious respiratory pathogens and personalized oncology markers, frequently forging alliances with academic centers to validate novel biomarkers. Technology providers are increasingly bundling software-as-a-service platforms with hardware sales, enabling real-time data analytics and remote monitoring capabilities that resonate with home care providers managing chronic conditions. Additionally, regional players are strengthening their foothold by tailoring lower-cost reagent sets and simplified instrument designs for resource-constrained settings. This strategic landscape underscores the importance of continuous innovation, cross-sector collaboration, and flexible commercialization models to sustain competitive advantage.

Strategic Imperatives to Navigate a Changing Market

Industry leaders must take decisive steps to navigate the complexities of this evolving market. First, they should diversify their supply chain to mitigate tariff-related cost fluctuations and explore partnerships with local manufacturers to enhance resilience. Second, integrating digital platforms with diagnostics offerings will unlock value through improved workflow efficiencies and data-driven decision support for clinicians and patients alike. Third, companies should align R&D investments with the fastest-growing segments-such as molecular diagnostics for infectious diseases and AI-enhanced imaging-to capture emerging revenue streams. Fourth, establishing strategic alliances with healthcare providers and research institutions can accelerate validation and market access, particularly in regions with stringent regulatory requirements. Finally, tailoring go-to-market strategies to distinct customer profiles-from geriatric pulmonary care programs to pediatric screening initiatives-will ensure relevance and foster deeper engagement across the continuum of care.

Robust Methodology Ensures Rigorous Market Insights

This report is underpinned by a rigorous methodology combining primary and secondary research. In-depth interviews with industry executives, laboratory directors, and clinician specialists provided firsthand perspectives on market trends, technology adoption, and regulatory impacts. Concurrently, extensive analysis of public filings, patent databases, and peer-reviewed literature supplied quantitative backing for qualitative insights. Data triangulation techniques were employed to reconcile disparate information sources, while a validation workshop with senior experts ensured the credibility of key findings. Segmentation frameworks were developed through iterative consultations, reflecting real-world diagnostic workflows and product categorizations. Throughout, adherence to ethical research standards and transparency protocols maintained the integrity of the process and minimized bias.

Synthesis of Key Findings for Informed Decision Making

The journey through the respiratory disease testing landscape reveals a market at the intersection of innovation, regulation, and shifting patient demands. Technological breakthroughs in molecular diagnostics and imaging, coupled with tariff revisions and evolving segment dynamics, underscore the need for agile strategies and informed decision making. Regional disparities highlight opportunities for targeted growth, while competitive analyses point to the imperative of continuous collaboration and product differentiation. By integrating these insights and following actionable recommendations, stakeholders can anticipate challenges, unlock new avenues for value creation, and ultimately deliver improved patient outcomes across diverse healthcare settings.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Test Type
    • Blood Tests
    • Imaging Tests
      • Chest X-Ray
      • Computed Tomography
    • Pulmonary Function Tests
  • Component
    • Instruments
    • Reagents & Kits
    • Software
  • Age Group
    • Adults
    • Geriatrics
    • Pediatrics
  • Technology
    • Imaging Technologies
    • Immunoassays
    • Microbiology
    • Molecular Diagnostics
  • Test Purpose
    • Diagnosis
    • Monitoring
    • Prognosis
    • Screening
  • Diseases Type
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
      • Chronic Bronchitis
      • Emphysema
    • Infectious Respiratory Diseases
      • Influenza
      • Pneumonia
      • Tuberculosis
    • Lung Cancer
  • End Users
    • Diagnostic Laboratories
    • Home Care Settings
    • Hospitals & Clinics
    • Research Laboratories
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Abbott Laboratories
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biomérieux PLC
  • Charles River Laboratories
  • COSMED srl
  • Eurofins Viracor, LLC
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings
  • GE Healthcare
  • Koninklijke Philips N.V
  • Medtronic PLC
  • MGC Diagnostics Corporation by Caire Inc.
  • QIAGEN Group
  • ResMed
  • SDI Diagnostics, Inc.
  • Seegene Inc.
  • Seimens Healthineers AG
  • Thermo Fisher Scientific

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Respiratory Disease Testing Market, by Test Type
8.1. Introduction
8.2. Blood Tests
8.3. Imaging Tests
8.3.1. Chest X-Ray
8.3.2. Computed Tomography
8.4. Pulmonary Function Tests
9. Respiratory Disease Testing Market, by Component
9.1. Introduction
9.2. Instruments
9.3. Reagents & Kits
9.4. Software
10. Respiratory Disease Testing Market, by Age Group
10.1. Introduction
10.2. Adults
10.3. Geriatrics
10.4. Pediatrics
11. Respiratory Disease Testing Market, by Technology
11.1. Introduction
11.2. Imaging Technologies
11.3. Immunoassays
11.4. Microbiology
11.5. Molecular Diagnostics
12. Respiratory Disease Testing Market, by Test Purpose
12.1. Introduction
12.2. Diagnosis
12.3. Monitoring
12.4. Prognosis
12.5. Screening
13. Respiratory Disease Testing Market, by Diseases Type
13.1. Introduction
13.2. Asthma
13.3. Chronic Obstructive Pulmonary Disease (COPD)
13.3.1. Chronic Bronchitis
13.3.2. Emphysema
13.4. Infectious Respiratory Diseases
13.4.1. Influenza
13.4.2. Pneumonia
13.4.3. Tuberculosis
13.5. Lung Cancer
14. Respiratory Disease Testing Market, by End Users
14.1. Introduction
14.2. Diagnostic Laboratories
14.3. Home Care Settings
14.4. Hospitals & Clinics
14.5. Research Laboratories
15. Americas Respiratory Disease Testing Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Respiratory Disease Testing Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Respiratory Disease Testing Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories
18.3.2. AstraZeneca PLC
18.3.3. Becton, Dickinson and Company
18.3.4. Bio-Rad Laboratories, Inc.
18.3.5. Biomérieux PLC
18.3.6. Charles River Laboratories
18.3.7. COSMED srl
18.3.8. Eurofins Viracor, LLC
18.3.9. F. Hoffmann-La Roche Ltd.
18.3.10. Fujifilm Holdings
18.3.11. GE Healthcare
18.3.12. Koninklijke Philips N.V
18.3.13. Medtronic PLC
18.3.14. MGC Diagnostics Corporation by Caire Inc.
18.3.15. QIAGEN Group
18.3.16. ResMed
18.3.17. SDI Diagnostics, Inc.
18.3.18. Seegene Inc.
18.3.19. Seimens Healthineers AG
18.3.20. Thermo Fisher Scientific
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. RESPIRATORY DISEASE TESTING MARKET MULTI-CURRENCY
FIGURE 2. RESPIRATORY DISEASE TESTING MARKET MULTI-LANGUAGE
FIGURE 3. RESPIRATORY DISEASE TESTING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. RESPIRATORY DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. RESPIRATORY DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RESPIRATORY DISEASE TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 56. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 77. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 79. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 80. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 81. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 82. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 83. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 84. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 85. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 86. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 87. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 88. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 90. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 92. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 93. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 95. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 96. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 97. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 98. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 110. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 120. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 121. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 122. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 127. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 129. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 131. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 132. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 133. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 134. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 135. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 137. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 138. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 139. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 140. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 141. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 142. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 143. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 144. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 145. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 146. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 147. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 148. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 149. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 150. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 151. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 152. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 153. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 156. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 157. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 158. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 159. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 161. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 162. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 163. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 164. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 165. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 166. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 167. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 168. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 169. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 170. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 171. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 177. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 179. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 180. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 181. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 182. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 183. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 184. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 185. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 186. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 187. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 188. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 189. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 190. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 191. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 192. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 193. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 194. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 195. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 196. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 197. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 198. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 199. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 200. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 202. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 206. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 207. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 208. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 209. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 210. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 211. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 212. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 213. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 214. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 215. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 216. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 217. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 218. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 219. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 220. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 221. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 222. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 223. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 224. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 225. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 226. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 227. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 228. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 229. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 230. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 231. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 232. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 233. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 234. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 235. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 236. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 237. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 238. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 239. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 240. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 252. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 253. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 254. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 255. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 256. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 258. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 259. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 260. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 261. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 262. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 263. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 264. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 265. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 266. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 267. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 268. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 269. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 270. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 271. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 272. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 273. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 274. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 275. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 276. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 277. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 278. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 279. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 280. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 281. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 282. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 283. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 284. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 285. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 286. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 287. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 288. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 289. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 290. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 291. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 292. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 293. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 294. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 295. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 296. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 297. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 298. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 299. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 300. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 301. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 302. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 303. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 304. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 305. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 306. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 307. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 308. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 309. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULM

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Respiratory Disease Testing market report include:
  • Abbott Laboratories
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biomérieux PLC
  • Charles River Laboratories
  • COSMED srl
  • Eurofins Viracor, LLC
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings
  • GE Healthcare
  • Koninklijke Philips N.V
  • Medtronic PLC
  • MGC Diagnostics Corporation by Caire Inc.
  • QIAGEN Group
  • ResMed
  • SDI Diagnostics, Inc.
  • Seegene Inc.
  • Seimens Healthineers AG
  • Thermo Fisher Scientific

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.86 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.18 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Respiratory Disease Testing - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Respiratory Disease Testing - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Global Respiratory Disease Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Global Respiratory Disease Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 120 Pages
  • Global
From
Respiratory Disease Testing Market Report 2025 - Product Image

Respiratory Disease Testing Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Respiratory Disease Testing - Global Strategic Business Report - Product Image

Respiratory Disease Testing - Global Strategic Business Report

  • Report
  • 158 Pages
  • Global
From
2025 Global Respiratory Disease Testing Market: Unmet Needs, Supplier Shares and Strategies, Volume and Sales Segmen Forecasts for Major Assays, Emerging Technologies and Trends, Growth Opportunities for Suppliers - Product Image

2025 Global Respiratory Disease Testing Market: Unmet Needs, Supplier Shares and Strategies, Volume and Sales Segmen Forecasts for Major Assays, Emerging Technologies and Trends, Growth Opportunities for Suppliers

  • Report
  • Global
From

About the Market

The Respiratory Disease Test market within the context of Diagnostics is a rapidly growing sector, as respiratory diseases are among the most common illnesses worldwide. Tests for respiratory diseases are used to diagnose and monitor a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), and pneumonia. These tests can be conducted in a variety of ways, including imaging tests, pulmonary function tests, and laboratory tests. Imaging tests such as X-rays and CT scans are used to detect abnormalities in the lungs, while pulmonary function tests measure the amount of air a person can inhale and exhale. Laboratory tests, such as sputum tests, are used to detect the presence of bacteria or viruses in the lungs. Some companies in the Respiratory Disease Test market include Abbott Laboratories, Becton Dickinson, Siemens Healthineers, Roche Diagnostics, and Thermo Fisher Scientific. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.